A team led by researchers at the Swiss Federal Institute of Technology Zurich and the Institute for Systems Biology has developed selected-reaction monitoring mass spec assays for more than 1,000 cancer related proteins in plasma and urine.

The researchers also demonstrated the potential of SRM-MS to efficiently verify candidate protein biomarkers, using the technique to evaluate the usefulness of 30 target proteins added to the existing five-protein panel of Vermillion's OVA1 ovarian cancer diagnostic.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.